No insider purchase over the last 90 days. The latest, by 김이환, was filed 09 Apr 2026.
Who traded when
BuySaleSince the insiders bought
- -29.8%Entry ₩302,000 · Close 30 Oct 2026 ₩212,000
- -38.6%Entry ₩345,000 · Close 30 Oct 2026 ₩212,000
- -58.8%Entry ₩515,000 · Close 30 Oct 2026 ₩212,000
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate PharmaResearch Co., Ltd. Strong Buy (bullish), based on 15 analysts. Average price target: ₩486,133.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- 350 shares@ ₩290,714.000.0023% mcap100.0% of flowShareKRXDART:20260409001074Canonical exit: 5 Jul 2026 (T+90)
- ●Executives0DART
- 80 sharesShareKRXDART:20260212000588Canonical exit: 13 May 2026 (T+90)
- 132 sharesShareKRXDART:20260127000112Canonical exit: 27 Apr 2026 (T+90)
- 94,924 sharesKRXDART:20260106000376
- 551,265 sharesKRXDART:20251216000323Canonical exit: 10 Mar 2026 (T+90)
- 480 sharesShareKRXDART:20251103000074
- ●Executives0DART
- 53,579 sharesKRXDART:20250106000284
- 1,175,647 sharesShareKRXDART:20241016000278Canonical exit: 14 Jan 2025 (T+90)
- 1,174,250 sharesKRXDART:20241016000272Canonical exit: 7 Jan 2025 (T+90)
- 112,792 sharesKRXDART:20240702000380
- 112,792 sharesKRXDART:20240509000019
- ShareKRXDART:20231201000009
- ShareKRXDART:20231127000309
- ShareKRXDART:20231113000497
- ShareKRXDART:20231106000109
- ShareKRXDART:20231019000164
- ShareKRXDART:20231016000130
- ShareKRXDART:20231016000127
- ShareKRXDART:20231011000468
- 112,792 sharesKRXDART:20231004000371
- 112,792 sharesKRXDART:20230904000100
- ShareKRXDART:20230904000062
25 of 41 declarations
About PharmaResearch Co., Ltd.
국민연금공단 dominates the filings at PharmaResearch Co., Ltd. (파마리서치): 17 filings, filed as 대량보유자 (large holder), with 16 sales and a single purchase. The Korean healthcare company, with a market capitalisation of KRW 2,732.5 billion, has 40 filings published between April 23, 2021 and April 9, 2026, and its sales (18) clearly outnumber purchases (7), or 28% purchases among open-market trades.
The one purchase with an amount, EUR 58,404, is 김이환's, listed as 재무관리본부장 (head of finance), on April 6, 2026. PolishCompanyLimited, filed as 주요주주 (major shareholder), files 12, including 1 purchase, and Morganstanley&cointlplc files 2, one purchase and one sale. 파마리서치 files 4 for its own account. From January 27 to February 12, 2026, 2 filers bought.
Read moreShow less
Volume peaked in 2023 with 18 filings, against 5 in each of 2021 and 2026, and 4 in each of 2022, 2024 and 2025. The latest twelve months hold 7 filings, 4 purchases and 2 sales. All filings together: median delay of 6 days. Insiders hold 35% of the capital.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
